Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies

Brain

Volumn 135, Issue 8, 2012, Pages 2470-2477

  Graff Radford, Jonathan ^a   Boeve, Bradley F ^a   Pedraza, Otto ^b   Ferman, Tanis J ^b   Przybelski, Scott ^a   Lesnick, Timothy G ^a   Vemuri, Prashanthi ^a   Senjem, Matthew L ^a   Smith, Glenn E ^a   Knopman, David S ^a   Lowe, Val ^a   Jack, Clifford R ^a   Petersen, Ronald C ^a   Kantarci, Kejal ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

acetylcholinesterase inhibitors; amyloid; dementia with Lewy bodies; MRI; PET; PiB

Indexed keywords

AMFEBUTAMONE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CARBIDOPA; CITALOPRAM; DONEPEZIL; FLUOXETINE; GALANTAMINE; LEVODOPA; MEMANTINE; PAROXETINE; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SERTRALINE; TRAZODONE; VENLAFAXINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; CEREBELLUM; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DEMENTIA RATING SCALE; FEMALE; FOLLOW UP; GRAY MATTER; HIPPOCAMPUS; HUMAN; IMAGE ANALYSIS; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NERVE DEGENERATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; RETROSPECTIVE STUDY; TEMPORAL LOBE; TREATMENT RESPONSE;

EID: 84864646977     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws173     Document Type: Article

References (43)

1. Burton EJ, Barber R, Mukaetova-Ladinska EB, Robson J, Perry RH, Jaros E, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 2009; 132: 195-203.
2. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med 1992; 327: 1253-9.
3. Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974; 30: 113-21.
4. Dubois B, McKeith I, Orgogozo JM, Collins O, Meulien D. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study. Int J Geriatr Psychiatry 1999; 14: 973-82.
5. Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer's disease. Lancet 1991; 337: 989-92.
6. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008; 79: 1331-8.
7. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 2010; 32: 1234-51.
8. Ferman TJ, Boeve BF, Smith GE, Lin SC, Silber MH, Pedraza O, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology 2011; 77: 875-82.
9. Ferman TJ, Smith GE, Boeve BF, Graff-Radford NR, Lucas JA, Knopman DS, et al. Neuropsychological differentiation of dementia with Lewy bodies from normal aging and Alzheimer's disease. Clin Neuropsychol 2006; 20: 623-36.
10. Firbank MJ, Blamire AM, Teodorczuk A, Teper E, Burton EJ, Mitra D, et al. High resolution imaging of the medial temporal lobe in Alzheimer's disease and dementia with Lewy bodies. J Alzheimers Dis 2010; 21: 1129-40.
11. Forstl H, Burns A, Luthert P, Cairns N, Levy R. The Lewy-body variant of Alzheimer's disease. Clinical and pathological findings. Br J Psychiatry 1993; 162: 385-92.
12. Foster ER, Campbell MC, Burack MA, Hartlein J, Flores HP, Cairns NJ, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord 2010; 25: 2516-23.
13. Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994; 51: 888-95.
14. Gomez-Isla T, Growdon WB, McNamara M, Newell K, Gomez-Tortosa E, Hedley-Whyte ET, et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999; 53: 2003-9.
15. Hanyu H, Shimizu S, Tanaka Y, Hirao K, Iwamoto T, Abe K. MR features of the substantia innominata and therapeutic implications in dementias. Neurobiol Aging 2007; 28: 548-54.
16. Ivnik RJ, Malec JF, Smith GE, Tangalos EG, Petersen RC, Kokmen E, et al. Mayo's Older Americans Normative Studies: WAIS-R, WMS-R and AVLT norms for ages 56 through 97. Clin Neuropsychol 1992; 6 (Suppl): 1-104.
17. Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131: 665-80.
18. Jurica PJ, Leitten CL, Mattis S, editors. Dementia rating scale-2: Professional manual. Lutz, FL: Psychological Assessment Resources; 2001.
19. Kantarci K, Dickson DW, Vemuri P, Ferman TJ, Boeve BF, Smith GE, et al. Ante mortem hippocampal atrophy predicts presence of Alzheimer's disease pathology in pathologically proven Lewy body disease. Neurology 2012.
20. Kantarci K, Lowe VJ, Boeve BF, Weigand SD, Senjem ML, Przybelski SA, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2011; 77: 875-82.
21. Kantarci K, Yang C, Schneider JA, Senjem ML, Reyes DA, Lowe VJ, et al. Ante mortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging 2012; 33: 878-85.
22. Levy R, Eagger S, Griffiths M, Perry E, Honavar M, Dean A, et al. Lewy bodies and response to tacrine in Alzheimer's disease. Lancet 1994; 343: 176.
23. Lowe VJ, Kemp BJ, Jack CR Jr, Senjem M, Weigand S, Shiung M, et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 2009; 50: 878-86.
24. Lucas JA, Ivnik RJ, Smith GE, Bohac DL, Tangalos EG, Kokmen E, et al. Normative data for the Mattis Dementia Rating Scale. J Clin Exp Neuropsychol 1998; 20: 536-47.
25. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009; 34: 107-12.
26. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-6.
27. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-72.
28. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-24.
29. Meltzer CC, Kinahan PE, Greer PJ, Nichols TE, Comtat C, Cantwell MN, et al. Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med 1999; 40: 2053-65.
30. Mori T, Ikeda M, Fukuhara R, Nestor PJ, Tanabe H. Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB. Neurology 2006; 66: 935-7.
31. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998; 50: 1222-30.
32. Pakrasi S, Mukaetova-Ladinska EB, McKeith IG, O'Brien JT. Clinical predictors of response to acetyl cholinesterase inhibitors: experience from routine clinical use in Newcastle. Int J Geriatr Psychiatry 2003; 18: 879-86.
33. Pedraza O, Smith GE, Ivnik RJ, Willis FB, Ferman TJ, Petersen RC, et al. Reliable change on the dementia rating scale. J Int Neuropsychol Soc 2007; 13: 716-20.
34. Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994; 5: 747-9.
35. Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson's and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993; 7: 69-79.
36. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-25.
37. Sabattoli F, Boccardi M, Galluzzi S, Treves A, Thompson PM, Frisoni GB. Hippocampal shape differences in dementia with Lewy bodies. NeuroImage 2008; 41: 699-705.
38. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197-204.
39. Tiraboschi P, Hansen LA, Alford M, Merdes A, Masliah E, Thal LJ, et al. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry 2002; 59: 946-51.
40. Vemuri P, Simon G, Kantarci K, Whitwell JL, Senjem ML, Przybelski SA, et al. Antemortem differential diagnosis of dementia pathology using structural MRI: differential-STAND. Neuroimage 2011; 55: 522-31.
41. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215: 1237-9.
42. Whitwell JL, Weigand SD, Shiung MM, Boeve BF, Ferman TJ, Smith GE, et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 2007; 130: 708-19.
43. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-95.